. 2022 Jul 11;30(1):357–367. doi: 10.1007/s12350-022-02986-7

Table 3.

Results for cardiac amyloidosis patients with and without PNP regarding visual Perugini score and quantitative whole-body and skull DPD uptake as well as femur to soft tissue and humerus to soft tissue ratios

	Group 1 – cATTR	Group 2- cATTR without DM
Perugini score PNP vs no PNP	(2.51 ± 0.51 vs 2.13 ± 0.52; P = 0.03) (N = 50; 35 vs 15 pat.)	(2.62 ± 0.49 vs 2.08 ± 0.29; P = 0.001) (N = 41; 29 vs 12 pat.)
Whole-body Uptake [cts/MBq] PNP vs no PNP	1928 ± 291 vs 1867 ± 272; P = 0.51 (N = 45; 31 vs 14 pat.)	1926 ± 309 vs 1875 ± 247; P = 0.63 (N = 36; 25 vs 11 pat.)
Skull uptake PNP vs no PNP [cts/MBq]	1.24 ± 0.44 vs 1.68 ± 0.63; P = 0.01 (N = 45; 31 vs 14 pat.)	1.20 ± 0.46 vs 1.76 ± 0.62; P = 0.01 (N = 36; 25 vs 11 pat.)
Soft tissue/Femoral shaft PNP vs no PNP	0.96 ± 0.14 vs 0.89 ± 0.16; P = 0.11 (N = 45; 31 vs 14 pat.)	0.97 ± 0.14 vs 0.88 ± 0.12; P = 0.07 (N = 36; 25 vs 11 pat.)
Soft tissue/humeral shaft PNP vs no PNP	0.91 ± 0.36 vs 0.83 ± 0.24; P = 0.49 (N = 45; 31 vs 14 pat.)	0.94 ± 0.39 vs 0.83 ± 0.26; P = 0.37 (N = 36; 25 vs 11 pat.)

Group 1 – cATTR

Group 2- cATTR without DM

Perugini score

PNP vs no PNP

(2.51 ± 0.51 vs 2.13 ± 0.52; P = 0.03)

(N = 50; 35 vs 15 pat.)

(2.62 ± 0.49 vs 2.08 ± 0.29; P = 0.001)

(N = 41; 29 vs 12 pat.)

Whole-body Uptake [cts/MBq]

PNP vs no PNP

1928 ± 291 vs 1867 ± 272; P = 0.51

(N = 45; 31 vs 14 pat.)

1926 ± 309 vs 1875 ± 247; P = 0.63

(N = 36; 25 vs 11 pat.)

Skull uptake

PNP vs no PNP [cts/MBq]

1.24 ± 0.44 vs 1.68 ± 0.63; P = 0.01

(N = 45; 31 vs 14 pat.)

1.20 ± 0.46 vs 1.76 ± 0.62; P = 0.01

(N = 36; 25 vs 11 pat.)

Soft tissue/Femoral shaft

PNP vs no PNP

0.96 ± 0.14 vs 0.89 ± 0.16; P = 0.11

(N = 45; 31 vs 14 pat.)

0.97 ± 0.14 vs 0.88 ± 0.12; P = 0.07

(N = 36; 25 vs 11 pat.)

Soft tissue/humeral shaft

PNP vs no PNP

0.91 ± 0.36 vs 0.83 ± 0.24; P = 0.49

(N = 45; 31 vs 14 pat.)

0.94 ± 0.39 vs 0.83 ± 0.26; P = 0.37

(N = 36; 25 vs 11 pat.)